DEF 14A: Acutus Medical Sets Date for 2024 Annual Stockholders Meeting

Acutus Medical will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, to elect directors and ratify the selection of KPMG LLP as its independent accounting firm.

Summary

• Acutus Medical, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, at 8:00 a.m. Pacific Time.
• Stockholders of record as of April 15, 2024, are eligible to vote.
• The meeting will address the election of two Class I directors, the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and any other business properly brought before the meeting.
• Proxy materials are being distributed to stockholders on or about April 25, 2024.
• The Board of Directors recommends voting for the election of the director nominees and for the ratification of KPMG LLP.
• Stockholders can vote online, by telephone, by mail, or virtually during the meeting.
• The company is an emerging growth company and a smaller reporting company, which allows for certain exemptions from reporting requirements.
• The Board of Directors knows of no other matters to come before the Annual Meeting other than the matters referred to in this Proxy Statement.

Sentiment

Score: 6

Explanation: The document is primarily informational and procedural, with a neutral tone. The inclusion of legal proceedings introduces a slightly negative element, but the overall sentiment is balanced.

Positives

• The Annual Meeting will be held virtually, which is expected to increase stockholder attendance and participation while reducing costs.
• Stockholders have multiple options for voting, including online, telephone, mail, and virtual attendance.
• The Board of Directors is actively engaged in risk oversight and corporate governance.
• The Audit Committee is comprised of independent and financially literate members.
• The company has a Compensation Recoupment Policy in place.

Negatives

• The company is involved in two putative securities class action lawsuits.
• Biotronik SE & Co. KG, Germany (Biotronik) and VascoMed GmbH, Germany (collectively, the Biotronik Parties) filed a Demand for Arbitration and Statement of Claim against the Company with the American Arbitration Association (who notified the Company of the filing on February 29, 2024), alleging that the Company breached its contractual obligations under five agreements relating to the licensing, manufacturing, distribution and development of certain medical devices as a result of the wind down of its mapping and ablation businesses.

Risks

• The company is subject to ongoing legal proceedings, including securities class action lawsuits and an arbitration demand from Biotronik, which could result in significant costs and liabilities.
• As an emerging growth company and smaller reporting company, Acutus Medical is exempt from certain reporting requirements, which may limit the information available to investors.
• The company's success depends on the effective oversight and guidance of its Board of Directors, and any disruptions or failures in governance could negatively impact performance.
• The company's anti-hedging and anti-pledging policy could limit the ability of employees, officers, and directors to manage their financial risks associated with holding company securities.

Future Outlook

The company is soliciting proxies for the 2024 Annual Meeting and intends to file final voting results with the SEC.

Management Comments

• Takeo Mukai, Chief Executive Officer and Chief Financial Officer: 'ALL STOCKHOLDERS ARE CORDIALLY INVITED TO VIRTUALLY ATTEND THE ANNUAL MEETING. WHETHER OR NOT YOU EXPECT TO ATTEND THE ANNUAL MEETING, PLEASE COMPLETE, DATE, SIGN AND RETURN THE PROXY CARD, OR VOTE OVER THE TELEPHONE OR INTERNET AS INSTRUCTED IN THESE MATERIALS, AS PROMPTLY AS POSSIBLE IN ORDER TO ENSURE YOUR REPRESENTATION AT THE ANNUAL MEETING.'

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including the solicitation of proxies, election of directors, and ratification of the selection of an independent accounting firm. The virtual-only meeting format aligns with a growing trend to increase accessibility and reduce costs.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity awards, is typical for companies of similar size and stage.
• The company's committee structure (Audit, Compensation, Nominating and Corporate Governance) aligns with best practices for corporate governance.
• The indemnification agreements with directors and officers are standard practice to attract and retain qualified individuals.
• The related party transaction policy is consistent with regulatory requirements and aims to ensure transparency and fairness.

Management Changes

Corporate Governance

Legal Proceedings

• The Company and certain of its current and former officers have been named as defendants in two putative securities class action lawsuits filed by putative stockholders in the United States District Court for the Southern District of California on February 15, 2022 and March 23, 2022 (case numbers 22CV206 and 22CV0388).
• On February 16, 2024, Biotronik SE & Co. KG, Germany (Biotronik) and VascoMed GmbH, Germany (collectively, the Biotronik Parties) filed a Demand for Arbitration and Statement of Claim against the Company with the American Arbitration Association (who notified the Company of the filing on February 29, 2024), alleging that the Company breached its contractual obligations under five agreements relating to the licensing, manufacturing, distribution and development of certain medical devices as a result of the wind down of its mapping and ablation businesses.

Related Party Transactions

• The company has entered into a credit agreement with lenders who are also principal stockholders.
• Dr. Bonita, a director, is a General Partner at OrbiMed Advisors, which has affiliations with lenders and stockholders.
• Dr. ElBardissi, a director, is a member of the private transaction team of Deerfield Management, which has affiliations with lenders and stockholders.
• The company has entered into indemnification agreements with its directors and executive officers.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will shape the company's governance and direction.
• Employees may be affected by changes in executive compensation and the termination of the ESPP.
• Customers and suppliers may be impacted by the company's restructuring and realignment of resources.
• Creditors are affected by amendments to the credit agreement and the company's financial performance.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Stockholders on June 13, 2024.
• The company will file the final voting results with the SEC.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Stockholders, Election of Directors, KPMG, Independent Registered Public Accounting Firm, Corporate Governance, Executive Compensation, Related Party Transactions, Risk Oversight, Emerging Growth Company, Smaller Reporting Company, Legal Proceedings